ESSA Pharma Inc (TSE:EPI) (NASDAQ:EPIX)‘s stock had its “buy” rating reaffirmed by research analysts at Dawson James in a research report issued on Wednesday.

Separately, Bloom Burton reaffirmed a “buy” rating on shares of ESSA Pharma in a research note on Thursday, May 18th.

ESSA Pharma (EPI) opened at 0.45 on Wednesday. The firm’s market cap is $13.09 million. ESSA Pharma has a 52 week low of $0.38 and a 52 week high of $4.60. The firm’s 50 day moving average price is $0.62 and its 200-day moving average price is $2.31.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/essa-pharma-inc-epi-given-buy-rating-at-dawson-james.html.

ESSA Pharma Company Profile

ESSA Pharma Inc is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR).

Receive News & Ratings for ESSA Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.